Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 6/20 | 0.59 |
| ▸ | CDK7 | P50613 | 3/20 | 0.57 |
| ▸ | CCNH | P51946 | 3/20 | 0.57 |
| ▸ | BTK | Q06187 | 4/20 | 0.56 |
| ▸ | ITK | Q08881 | 2/20 | 0.56 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.56 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.56 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.55 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.55 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.55 |
| ▸ | ABL1 | P00519 | 7/20 | 0.54 |
| ▸ | BCR | P11274 | 7/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.54 |
| ▸ | PRKCA | P17252 | 4/20 | 0.54 |
| ▸ | SRC | P12931 | 3/20 | 0.54 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.54 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.54 |
| ▸ | PRKCG | P05129 | 1/20 | 0.54 |
| ▸ | PRKCB | P05771 | 1/20 | 0.54 |
| ▸ | PRKCH | P24723 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14979754 | 0.93 | BTK (0.56) | PDGFRACDK7CCNHBTKITK | |
| SCHEMBL18313107 | 0.85 | CDK7 (0.76) | CDK7CCNHBTKPIP4K2APIP4K2B | |
| SCHEMBL14979753 | 0.85 | PDGFRA (0.79) | PDGFRABTKITKMAPK8MAPK9 | |
| SCHEMBL14979759 | 0.82 | PDGFRA (0.77) | PDGFRABTKITKMAPK8MAPK9 | |
| SCHEMBL18346151 | 0.82 | CDK7 (0.56) | PDGFRACDK7CCNHBTKITK | |
| SCHEMBL29644767 | 0.78 | PDGFRA (0.73) | PDGFRABTKITKMAPK8MAPK9 | |
| SCHEMBL14979760 | 0.78 | PDGFRA (0.73) | PDGFRABTKITKMAPK8MAPK9 | |
| SCHEMBL20204854 | 0.77 | ABL1 (0.72) | PDGFRAMAPK8MAPK9MAPK10ABL1 | |
| SCHEMBL22606038 | 0.76 | CDK7 (0.68) | CDK7CCNHBTKMAPK8MAPK9 | |
| SCHEMBL20998475 | 0.76 | PLK1 (0.57) | PDGFRABTKABL1BCRPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153730-A9 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-20210300911-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| WO-2021133601-A1 | THE COMBINATION OF CYCLIN DEPENDENT KINASE 7 INHIBITOR AND IMMUNOTHERAPY FOR TREATMENT OF CANCER | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
| US-10981903-B2 | Inhibitors of c-Jun-N-terminal kinase (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200338074-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-10787436-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-10702527-B2 | Combination therapy of transcription inhibitors and kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20200197392-A1 | COMPOSITIONS AND METHODS FOR TREATING TUBEROUS SCLEROSIS COMPLEX | THE BRIGHAM & WOMEN'S HOSPITAL, INC. (US) | 2020-06-25 | — | — | US | disclosed |
| US-20200087295-A9 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-03-19 | — | — | US | disclosed |
| EP-3569598-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | Dana Farber Cancer Institute, Inc. (US) | 2019-11-20 | — | — | EP | disclosed |
| US-20190248778-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-08-15 | — | — | US | disclosed |
| EP-2822935-B1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | DANA FARBER CANCER INST INC (US) | 2019-05-15 | — | — | EP | disclosed |
| US-20190100511-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-04 | — | — | US | disclosed |
| US-20190015411-A9 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-20160368910-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-12-22 | — | — | US | disclosed |
| WO-2016201370-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| US-9382239-B2 | Inhibitors of c-Jun-N-terminal kinase (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20140309249-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | Dana-Farber Cancer Intitute, Inc. (US) | 2014-10-16 | — | — | US | disclosed |
| WO-2013074986-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190100511-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK9, CDK6 | PDGFRA 4248/4885CDK7 1/4885CCNH 32/4885 |
| US-10702527-B2 | Combination therapy of transcription inhibitors and kinase inhibitors | CHUK, BCOR, MYC | PDGFRA 875/4885CDK7 130/4885CCNH 539/4885 |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | PDGFRA 875/4885CDK7 130/4885CCNH 539/4885 |
| US-10981903-B2 | Inhibitors of c-Jun-N-terminal kinase (JNK) | CNKSR1, MAPK1, MAP3K1 | PDGFRA 2050/4885CDK7 129/4885CCNH 292/4885 |
| US-20200197392-A1 | COMPOSITIONS AND METHODS FOR TREATING TUBEROUS SCLEROSIS COMPLEX | CDK7, CDK17, MTOR | PDGFRA 2829/4885CDK7 1/4885CCNH 16/4885 |
| US-20210300911-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | CNKSR1, MAPK1, MAP3K1 | PDGFRA 2050/4885CDK7 129/4885CCNH 292/4885 |
| US-20200087295-A9 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | CNKSR1, MAPK1, MAP3K1 | PDGFRA 2050/4885CDK7 129/4885CCNH 292/4885 |
| US-20220153730-A9 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | CNKSR1, MAPK1, MAP3K1 | PDGFRA 2050/4885CDK7 129/4885CCNH 292/4885 |
| US-20190015411-A9 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | PDGFRA 875/4885CDK7 130/4885CCNH 539/4885 |
| US-20160368910-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | CNKSR1, MAPK1, MAP3K1 | PDGFRA 2050/4885CDK7 129/4885CCNH 292/4885 |
| US-20140309249-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | CNKSR1, MAPK1, MAP3K1 | PDGFRA 2050/4885CDK7 129/4885CCNH 292/4885 |
| US-20190248778-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | CNKSR1, MAPK1, MAP3K1 | PDGFRA 2050/4885CDK7 129/4885CCNH 292/4885 |
| US-20200338074-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | PDGFRA 875/4885CDK7 130/4885CCNH 539/4885 |
| US-10787436-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK9, CDK6 | PDGFRA 4248/4885CDK7 1/4885CCNH 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.